Authors: Sophie Liabeuf, Gaye Hafez, Vesna Pešić, Goce Spasovski, Mickael Bobot, Romaldas Mačiulaitis, Inga Arune Bumblyte, Ana Carina Ferreira, Ana Farinha, Jolanta Malyszko, Marion Pépin, Ziad A Massy, Robert Unwin, Giovambattista Capasso, Laila-Yasmin Mani
Antibacterial agents (ABs) represent a critical component of therapy regimens in patients with CKD due to increased susceptibility to infections. Elucidating AB-induced cognitive effects in patients with CKD demands a comprehensive understanding and tailored therapeutic strategies that account for altered pharmacokinetics and the kidney-gut-brain axis.
Here is our third review: The drugs with a negative impact on cognitive functions
